LAVAL, Quebec, Aug. 15, 2018 /PRNewswire/ — Ortho Dermatologics, a division of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for…Original Article
Ortho Dermatologics Resubmits U.S. New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion
